Product on Market

Future drugs always have to be better than the preparations that are currently available. Clearly differentiated compounds that stand out from the mass of approaches and break new ground form the key value drivers in the pharmaceutical industry. MorphoSys’s technologies and the expertise of its employees support the search for drug candidates with these unique properties.

Tremfya® (guselkumab) (Janssen)

Guselkumab (CNTO1959) is a HuCAL-antibody specific to IL23p19 and is developed by Janssen Biotech/Johnson & Johnson. The program has concluded phase 2 clinical trials for the indications psoriasis, rheumatoid arthritis and palmoplantar pustulosis. In spring 2014, promising data from the phase 2b-trial in psoriasis have been published. The antibody is currently being evaluated in six phase 3-trials.

Guselkumab is a very good example of the power of HuCAL, the antibody having been engineered to be specific for IL23. The absolute specificity of guselkumab for IL23 is expected to translate into both efficacy and safety advantages.

More information about Tremfya® Study Information on ClinicalTrials.gov

Therapeutic pipeline

MorphoSys has established one of the broadest pipelines in the biopharmaceutical industry.
Therapeutic Pipeline